BioCardia pauses enrollment in PhIII trial of heart failure stem cell therapy
BioCardia has paused enrollment in a pivotal study of its stem cell therapy for heart failure after an independent review board determined the trial was …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.